Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

/EIN News/ -- WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the Company’s September 2024 initial public offering (“IPO”). Investors who suffered significant losses are encouraged to contact the firm.

[Click here for information about joining the class action]

CASE OVERVIEW: Zenas BioPharma, a clinical-stage biopharmaceutical company, held its IPO on or around September 13, 2024, selling approximately 13.2 million shares at $17.00 per share. A recently filed class action complaint alleges that the Zenas BioPharma, key executives, directors, and IPO underwriters made materially false and misleading statements in the Registration Statement by overstating the duration the company could sustain operations with its IPO proceeds and existing cash reserves.

In its third quarter 2024 report, Zenas BioPharma revised its estimate, stating it could fund operations for only 12 months, rather than the previously disclosed 24 months. Following this announcement, the company’s stock declined sharply—closing at $8.72 per share on April 15, 2025—representing a 48.7% drop from the IPO price.

INVESTOR OPTIONS: Investors who purchased Zenas BioPharma securities in the IPO and experienced financial losses have until June 16, 2025, to seek appointment as lead plaintiff. You do not need to seek appointment as lead plaintiff to be eligible to share in any potential recovery.

To learn more about this matter or discuss your rights, please contact Cohen Milstein partner Molly J. Bowen at (202) 408-4600 or mbowen@cohenmilstein.com.

ABOUT COHEN MILSTEIN: With over 100 attorneys across eight offices, Cohen Milstein is one of the nation’s premier plaintiffs’ law firms, known for securing significant recoveries in complex securities fraud cases. The firm recently recovered over $1 billion for investors as co-lead counsel in In re Wells Fargo & Company Securities Litigation. Recognized by The National Law Journal, Law360, Chambers USA, and The Legal 500, Cohen Milstein continues to set the standard for investor advocacy. Visit www.cohenmilstein.com to learn more.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:
Molly Bowen, Esq.
Licensed in DC, Florida, and Ohio
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W., Fifth Floor
Washington, D.C. 20005
Phone: (888) 240-0775 or (202) 408-4600
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com